The magnitude of GSK's reach is evidenced by a product portfolio that spans several therapeutic classes. The diverse platform insulates the company from problems with any single product.

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

The cancer portfolio also put in a buoyant ... climbed 41 per cent to £101 million. The latter product will of course not have an impact on GSK's future growth, as it is one of the oncology ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Pharma major GSK (LSE: GSK) on Tuesday said its urinary tract infection treatment gepotidacin, under the brand name Blujepa, ...

Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio The latest announcement is out from GlaxoSmithKline ( (GB:GSK)). GSK announced ...

Harvey Jones has spotted signs of life in the GSK share price. Which is a relief after its recent troubles, so can the FTSE ...

GSK (GSK) is pushing the UK government to give pharmaceutical companies more access to its public health data in order to accelerate drug ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK ... According to Andy Acker, portfolio manager at Janus Henderson Investors, “This may be the largest opportunity we ...

("GSK" or the "Company") (NYSE ... Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings.